ZOLEDRONIC ACID ROLE IN SRES PREVENTION: AN ADVANTAGE FOR ALL PATIENTS WITH ADVANCED NSCLC AND BONE METASTASES?

被引：0
|
作者：
Del Signore, E. [1 ]
De Marinis, F. [2 ]
机构：
[1] San Camillo Forlanini High Specializat Hosp, Rome, Italy
[2] AO San Camillo Forlanini, Dept Lung Dis, Rome, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S78 / S78
页数：1
相关论文
共 50 条
  • [31] Denosumab and zoledronic acid treatment in patients with genitourinary cancers and bone metastases
    Costa, Luis
    Fizazi, Karim
    Saad, Fred
    Brown, Janet Elizabeth
    Von Moos, Roger
    Oudard, Stephane
    Sternberg, Cora N.
    Ganju, Vinod
    Miller, Kurt
    Wang, Huei
    Maniar, Tapan
    Braun, Ada
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] NTX and VEGF in cancer patients with bone metastases treated with zoledronic acid
    Mercatali, L.
    Ibrahim, T.
    Sacanna, E.
    Ricci, R.
    Scarpi, E.
    Fabbri, F.
    Serra, P.
    Tison, C.
    Amadori, D.
    EJC SUPPLEMENTS, 2010, 8 (05): : 23 - 23
  • [33] Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases
    Faruk Tas
    Derya Duranyildiz
    Hilal Oguz
    Hakan Camlica
    Vildan Yasasever
    Erkan Topuz
    Medical Oncology, 2008, 25 : 346 - 349
  • [34] COST EFFECTIVENESS OF ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL RELATED EVENTS IN PROSTATE CANCER PATIENTS WITH BONE METASTASES IN FRANCE
    Meijboom, M.
    Botteman, M.
    Kaura, S.
    Durand-Zaleski, I.
    ANNALS OF ONCOLOGY, 2008, 19 : 201 - 201
  • [35] Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours
    Zheng, G. Z.
    Chang, B.
    Lin, F. X.
    Xie, D.
    Hu, Q. X.
    Yu, G. Y.
    Du, S. X.
    Li, X. D.
    EUROPEAN JOURNAL OF CANCER CARE, 2017, 26 (06)
  • [36] Zoledronic acid reduces bone resorption markers in patients with lytic and blastic bone metastases
    Saad, F
    Gleason, D
    Rosen, L
    Gordon, D
    BONE, 2002, 30 (03) : 53S - 53S
  • [37] Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid
    Pectasides, D
    Nikolaou, M
    Farmakis, D
    Kanakis, I
    Gaglia, A
    Kountourakis, P
    Karamanos, NK
    Economopoulos, T
    Raptis, SA
    ANTICANCER RESEARCH, 2005, 25 (2B) : 1457 - 1463
  • [38] DENOSUMAB IS SUPERIOR TO ZOLEDRONIC ACID FOR DELAYING OR PREVENTING SKELETAL RELATED EVENTS (SRES) IN BREAST CANCER PATIENTS WITH BONE METASTASES (BM): RESULTS OF A PHASE 3 TRIAL
    Body, J.
    Stopeck, A.
    Fujiwara, Y.
    Lipton, A.
    Steger, G. G.
    Viniegra, M.
    Fan, M.
    Dansey, R.
    Jun, S.
    Braun, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 60 - 60
  • [39] Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone Metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline
    Mystakidou, K
    Katsouda, E
    Parpa, E
    Kelekis, A
    Galanos, A
    Vlahos, L
    MEDICAL ONCOLOGY, 2005, 22 (02) : 195 - 201
  • [40] Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline
    Kyriaki Mystakidou
    Emmanuela Katsouda
    Efi Parpa
    Alexis Kelekis
    Antonis Galanos
    Lambros Vlahos
    Medical Oncology, 2005, 22 : 195 - 201
12345